Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 701–800 of 1,000
The diagnosis of hepatosplenic candidiasis by DNA analysis of tissue biopsy and serum
Kirby, A., Chapman, C., Hassan, C., & Burnie, J. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.015347 · Cited by 19
Christopeit, M., Eikam, M., & Behre, G. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01524.x · Cited by 16
Antifúngicos para uso sistémico
Ruíz-Camps, I., & Cuenca‐Estrella, M. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2009.04.001 · Cited by 41
Verma, A., WILLIAMS, S. F., Trifilio, S. M., Zembower, T., & Mehta, J. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704485 · Cited by 16
Management of Opportunistic Infections in Solid-Organ Transplantation
Chiu, L. M., Domagala, B., & Park, J. M. (2004) · Progress in Transplantation · doi:10.1177/152692480401400206 · Cited by 16
Poon, L. M., Chia, H., Tan, L. ‐., Liu, T. ‐., & Koh, L. P. (2009) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2009.00363.x · Cited by 16
Torres, H. A., Kontoyiannis, D. P., & Rolston, K. V. I. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0601-x · Cited by 18
A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia
Wilson, A. G., Micek, S. T., & Ritchie, D. J. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.08.007 · Cited by 19
Karthaus, M., & Cornely, O. A. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0986-0 · Cited by 18
New approaches to invasive fungal infections
Marr, K. A. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200311000-00009 · Cited by 18
Guidelines for Antibiotics Prescription in Critically Ill Patients
Chaudhry, D., Desai, M., Gupta, M., Mohan, A., Mehta, Y. B., Sengar, M., Govil, D., Hegde, A. V., Rungta, N., Mittal, S., et al. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24677 · Cited by 20
Bal, A. M., Pana, Z. D., Carlesse, F. A. D. M. C., Marek, A., Seidel, D., Mehler, K., Butzer, S., Sprute, R., Stemler, J., Ludwig-Bettin, D., et al. (2025) · Mycoses · doi:10.1111/myc.70041 · Cited by 16
Clinical Aspects of Invasive Candidiasis in Critically Ill Patients
Pennisi, M. A., & Antonelli, M. M. (2009) · Drugs · doi:10.2165/11315590-000000000-00000 · Cited by 16
Almyroudis, N. G., & Segal, B. H. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.141 · Cited by 16
Pappas, P. G., Kauffman, C. A., Andes, D. R., Benjamin, D. K., Calandra, T., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598961 · Cited by 26
Candidemia in the patient with malignancy
Alves, J., Palma, P., Azevedo, D., & Rello, J. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1508290 · Cited by 19
Choi, H., Kim, J. H., Seong, H., Lee, W. J., Jeong, W., Ahn, J. Y., Jeong, S. J., Ku, N. S., Yeom, J., Kim, Y. K., et al. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.03.039 · Cited by 15
Alonso‐Monge, R., Guirao-Abad, J. P., Sánchez-Fresneda, R., Plá, J., Yagüe, G., & Argüelles, J. C. (2020) · Microorganisms · doi:10.3390/microorganisms8121867 · Cited by 17
Sipsas, N. V., Lewis, R. E., RAAD, I. I., & Kontoyiannis, D. P. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.006 · Cited by 17
Kamysz, E., Simonetti, O., Cirioni, O., Arzeni, D., Ganzetti, G., Campanati, A., Giacometti, A., Gabrielli, E., Silvestri, C., Kamysz, W., et al. (2010) · Peptides · doi:10.1016/j.peptides.2010.10.022 · Cited by 15
Tratamiento de las infecciones fúngicas invasoras
Pachón, J., Cisneros, J. M., Collado, A., Lomas-Cabezas, J. M., de León, F. L., Parra-Ruiz, J., & Rivero-Román, A. (2006) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(06)73772-7 · Cited by 19
Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics
Stader, F., Würthwein, G., Groll, A. H., Vehreschild, J. J., Cornely, O. A., & Hempel, G. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1595-9 · Cited by 15
Management of candidaemia and invasive candidiasis in critically ill patients
Chahoud, J., Kanafani, Z. A., & Kanj, S. S. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.04.008 · Cited by 23
Tratamiento antifúngico empírico en pacientes seleccionados con fiebre persistente y neutropenia
Cisneros, J. M., Espigado, I., Rivero, A., de León, F. L., Parra, J., Collado, A., Lomas, J. M., & Pachón, J. (2005) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(05)75041-2 · Cited by 17
Rex, J. H., & Stevens, D. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00040-0 · Cited by 20
Antifungal management in cancer patients
Staber, P. B., Langner, S., Dornbusch, H. J., & Neumeister, P. (2007) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-007-0466-y · Cited by 17
Pancham, S., Hemmaway, C. J., New, H. V., Albert, E., Dokal, I. S., Roberts, I. A. G., & McCloy, M. (2005) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2005.00261.x · Cited by 16
Treatment options in candidaemia
Karthaus, M., & Cornely, O. A. (2007) · Mycoses · doi:10.1111/j.1439-0507.2007.01379.x · Cited by 19
Antifungal prophylaxis in the intensive care unit: Who should get it?*
Rex, J. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000208110.36504.19 · Cited by 15
Marr, K. A. (2008) · Clinical Infectious Diseases · doi:10.1086/528715 · Cited by 16
Enhancement of the antibiofilm activity of amphotericin B by polyamine biosynthesis inhibitors
Liao, Z., ZhangGuan, X., Zhu, Z., Yao, X., Yang, Y., Jiang, Y., & Cao, Y. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.02.021 · Cited by 15
Girmenia, C., Finolezzi, E., Federico, V., Santopietro, M., & Perrone, S. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.013 · Cited by 17
Kanji, J. N., Laverdière, M., Rotstein, C., Walsh, T. J., Shah, P. S., & Haider, S. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.745073 · Cited by 14
Self-citationUnveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin
Teixeira‐Santos, R., Ricardo, E., Branco, R. J. F., Azevedo, M. M., Rodrigues, A. G., & Pina‐Vaz, C. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01439 · Cited by 14
Shkalim‐Zemer, V., Levi, I., Fischer, S., Tamary, H., Yakobovich, J., Avrahami, G., Gilad, G., Elitzur, S., Yaniv, I., Elhasid, R., et al. (2017) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001844 · Cited by 15
Polat, S. H., Sharifynia, S., Öz, Y., Aslan, M., Gündoğdu, N., Serin, A., Rafati, H., Mohammadi, F., Metin, D. Y., Döğen, A., et al. (2018) · Mycopathologia · doi:10.1007/s11046-018-0261-x · Cited by 14
[Recommendations of antifungal treatment in patients with low grade immunosuppression].
Barberán, J., Mensa, J., Fariñas, C., Llinares, P., Serrano, R., Menéndez, R., Agustí, C., Gobernado, M., Azanza, J. R., & Rodríguez, J. A. G. (2008) · PubMed · Cited by 19
La caspofungine : du mécanisme d'action aux applications thérapeutiques
Datry, A., & Bart–Delabesse, E. (2005) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2005.05.012 · Cited by 18
New options for the treatment of invasive fungal infections
Rubin, Z., & Somani, J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.02.020 · Cited by 14
Safety and Potential of Drug Interactions of Caspofungin and Voriconazole in Multimorbid Patients
Kulemann, V., Bauer, M., Graninger, W., & Joukhadar, C. (2005) · Pharmacology · doi:10.1159/000088622 · Cited by 14
Of Yeasts and Hyphae: A Hematologist’s Approach to Antifungal Therapy
Bow, E. J. (2006) · Hematology · doi:10.1182/asheducation-2006.1.361 · Cited by 16
Caspofungin—a new therapeutic option for oropharyngeal candidiasis
Garbino, J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1198-743x.2004.00823.x · Cited by 14
Efficacy of micafungin for the treatment of candidemia
Andes, D. R., & Safdar, N. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0025-7 · Cited by 15
Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?
Eggimann, P., Wolff, M., & Garbino, J. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2806-y · Cited by 14
van der Elst, K. C. M., Brüggemann, R. J. M., Rodgers, M. G. G., & Alffenaar, J. C. (2012) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2011.00716.x · Cited by 15
Grau, S., Salavert, M., Laderas, J. C. P., Vargas, M., Barrueta, J. A., & Mir, N. (2013) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2013.05.004 · Cited by 15
Karthaus, M., Rüping, M. J. G. T., Cornely, O. A., Steinbach, A., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Vehreschild, J. J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01988.x · Cited by 14
Application of chemical biology in target identification and drug discovery
Zhu, Y., Xiao, T., Lei, S., Zhou, F., & Wang, M. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0643-2 · Cited by 13
Molecular targeted treatments for fungal infections: the role of drug combinations
Lupetti, A., Nibbering, P. H., Campa, M., Tacca, M. D., & Danesi, R. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00091-1 · Cited by 14
Bicanic, T. A., & Harrison, T. S. (2013) · Medicine · doi:10.1016/j.mpmed.2013.10.006 · Cited by 15
Morrison, V. A. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.5.697 · Cited by 13
Cui, N., Wang, H., Qiu, H., Li, R., & Liu, D. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.02.019 · Cited by 13
Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats
Leshinsky, J., McLachlan, A. J., Foster, D. J. R., Norris, R. L. G., & Barrs, V. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178783 · Cited by 15
Vehreschild, J. J., Rüping, M. J. G. T., Steinbach, A., & Cornely, O. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903405639 · Cited by 13
Pan, S., Hsieh, S., Chang, S., Lee, H.-T., & Chen, Y. (2005) · Medical Mycology · doi:10.1080/13693780500302593 · Cited by 15
Özcan, S. K., Budak, F., Willke, A., Filiz, S., Costur, P., & Dalçık, H. (2006) · Apmis · doi:10.1111/j.1600-0463.2006.apm_450.x · Cited by 13
Singh, D., & Bonomo, R. A. (2016) · InTech eBooks · doi:10.5772/64372 · Cited by 15
Candida : What Should Clinicians and Scientists Be Talking About?
Spellberg, B. J., Marr, K. A., & Filler, S. G. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch1 · Cited by 15
New antifungal drugs and new clinical trials: interpreting results may be difficult
Girmenia, C., & Martino, P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200307000-00001 · Cited by 17
Wingard, J. R., Nichols, W. G., & McDonald, G. B. (2004) · Hematology · doi:10.1182/asheducation-2004.1.372 · Cited by 14
Geersing, T. H., Franssen, E. J. F., Spronk, P. E., van Kan, H. J. M., den Reijer, M., & van der Voort, P. H. J. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab372 · Cited by 14
Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients
Ferrada, M. A., Quartin, A. A., Kett, D. H., & Morris, M. I. (2013) · BMC Anesthesiology · doi:10.1186/1471-2253-13-37 · Cited by 12
Recomendaciones para el manejo de la candidemia en neonatos en América Latina
Santolaya, M. E., Matute, T. A., Telles, F. D. Q., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.06.002 · Cited by 18
Self-citationAnidulafungin in the treatment of patients with invasive candidiasis
Kett, D. H., & Cubillos, G. F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70008-6 · Cited by 12
Infección fúngica invasiva en los pacientes ingresados en las áreas de críticos
Garnacho‐Montero, J., Díaz‐Martín, A., de Piappon, M. R. P., & García-Cabrera, E. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.02.011 · Cited by 24
Shoham, S., Groll, A. H., Petraitis, V., & Walsh, T. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00156-8 · Cited by 16
Lipopeptides: Status and Strategies to Control Fungal Infection
Baindara, P., & Korpole, S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2782-3_4 · Cited by 13
Shibata, Y., Hagihara, M., Kato, H., Kawasumi, N., Hirai, J., Nishiyama, N., Asai, N., Koizumi, Y., Yamagishi, Y., Matsuura, K., et al. (2017) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2017.02.008 · Cited by 12
Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans
Akins, R. A., & Sobel, J. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_29 · Cited by 15
Qin, J., Yang, H., Shan, Z., Jiang, L., & Zhang, Q. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001434 · Cited by 14
Komorowski, A. S., Bai, A. D., Cvetkovic, A., Mourad, O., Lo, C. K. L., Li, X. X., Mokashi, V., Findlater, A. R., Duncan, D. B., Fuller, C. J., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.003 · Cited by 15
JSMM Clinical Practice Guidelines for Diagnosis and Treatment of Invasive Candidiasis
(2013) · Medical Mycology Journal · doi:10.3314/mmj.54.147 · Cited by 12
Solomkin, J. S., & Umanskiy, K. (2003) · Current Opinion in Critical Care · doi:10.1097/00075198-200310000-00013 · Cited by 12
Traitement antifongique des candidoses systémiques en réanimation
Kettani, A., Belkhadir, Z. H., Mosadik, A., Faroudy, M., Ababou, A., Lazreq, C., & Sbihi, A. (2006) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2005.10.004 · Cited by 18
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Wiederhold, N. P., Cota, & Frei, C. R. (2009) · Infection and Drug Resistance · doi:10.2147/idr.s3864 · Cited by 19
An overview of fungal prophylaxis in lung transplantation
Covarrubias, M. B., & Milstone, A. P. (2005) · Current Opinion in Organ Transplantation · doi:10.1097/01.mot.0000169368.45884.2d · Cited by 12
Recommendations for the treatment of fungal pneumonias
Yamada, H., Kotaki, H., & Takahashi, T. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.8.1241 · Cited by 13
Special Topics in Cardiac Surgery
Narin, C. (2012) · InTech eBooks · doi:10.5772/2307 · Cited by 12
Systemic Candidiasis: Candidemia and Deep-Organ Infections
Clancy, C. J., & Nguyen, M. H. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch27 · Cited by 15
Successful treatment ofCandida kruseifungemia with amphotericin B and caspofungin
Olver, W. J., Scott, F., & Shankland, G. S. (2006) · Medical Mycology · doi:10.1080/13693780600686929 · Cited by 12
Fungal infections in bone marrow transplant recipients
Raman, T., & Marik, P. E. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.3.307 · Cited by 13
Micafungin for the prophylaxis and treatment ofCandidainfections
Fritz, J. M., Brielmaier, B. D., & Dubberke, E. R. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.2.153 · Cited by 15
Conen, A., Weisser, M., Jörg, C. O., Battegay, M., Trampuž, A., Frei, R., Christen, S. E., Heim, D. A., Gratwohl, A. A., & Flückiger, U. M. (2007) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2007.00238.x · Cited by 14
Walsh, T. J. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae257 · Cited by 14
Lewis, R. E. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ff7e10 · Cited by 12
Espinel‐Ingroff, A., & Cantón, E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70002-7 · Cited by 13
Caspofungin: when and how? The microbiologist’s view
Mayr, A., Aigner, M., & Lass‐Flörl, C. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02039.x · Cited by 13
Analytic Reviews: Postoperative Infectious Complications of Abdominal Solid Organ Transplantation
Hlava, N., Niemann, C. U., Gropper, M. A., & Melcher, M. L. (2008) · Journal of Intensive Care Medicine · doi:10.1177/0885066608327127 · Cited by 11
Echinocandins in invasive candidiasis
Simon, J., Sun, H., Leong, H. N., Barez, M. Y., Huang, P., Talwar, D., Wang, J.-H., Mansor, M. M., Wahjuprajitno, B., Patel, A. K., et al. (2013) · Mycoses · doi:10.1111/myc.12085 · Cited by 12
Ostrosky-Zeichner, L. L., Paetznick, V. L., Rodriguez, J., Chen, E., & Sheehan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00955-08 · Cited by 12
Lehrnbecher, T., Mousset, S., Sörensen, J., & Böhme, A. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01629.x · Cited by 14
Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal, M. B., Rathi, S., Ratho, N., & Subramanian, R. (2006) · PubMed · Cited by 14
Hübel, K., Chemnitz, J., Brochhagen, H. G., & Cornely, O. A. (2004) · International Journal of Hematology · doi:10.1532/ijh97.e0315 · Cited by 11
Popovich, K. J., Malani, P., Kauffman, C. A., & Cinti, S. K. (2007) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318059b95f · Cited by 11
Anidulafungin: a drug evaluation of a new echinocandin
Joseph, J., Kim, R., & Reboli, A. C. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.13.2339 · Cited by 11
Voriconazole for candidosis: an important addition?
Graybill, J. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67579-4 · Cited by 12
Nishida, R., Eriguchi, Y., Miyake, N., Nagasaki, Y., Yonekawa, A., Mori, Y., Kato, K., Akashi, K., & Shimono, N. (2023) · Medical Mycology · doi:10.1093/mmy/myad056 · Cited by 12
Duration of systemic antifungal therapy for patients with invasive fungal diseases: A reassessment
Gressens, S. B., Rouzaud, C., Lamoth, F., Calandra, T., Lanternier, F., & Lortholary, O. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101347 · Cited by 10
Update: invasive Pilzinfektionen
Lichtenstern, C., Swoboda, S., Hirschburger, M., Domann, E., Hoppe‐Tichy, T., Winkler, M., Lass‐Flörl, C., & Weigand, M. A. (2010) · Der Anaesthesist · doi:10.1007/s00101-009-1655-4 · Cited by 12
Aşçıoğlu, S., & Chan, K. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083658 · Cited by 11
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.